# Sling Therapeutics

> Clinical-stage biotech developing oral linsitinib for thyroid eye disease; closed a $123 million Series C.

## Why it is interesting

Sling has a low-difficulty brand query and a late-stage Phase 3 asset, making its funding record useful even if the absolute search volume is modest.

## Profile

- **Latest funding:** Series C — $123M (September 16, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $123M
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** Forbion, TPG Life Sciences Innovations, Sectoral Asset Management

## Key facts

- Sep 16, 2026: $123M Series C
- Forbion led the round
- Capital supports the Phase 3 ORBIT program

## Funding history

- Series C · $123M · September 16, 2026
  Source: https://slingtx.com/2026/09/16/sling-therapeutics-announces-123-million-series-c-financing-to-advance-phase-3-development-of-its-oral-small-molecule-igf-1r-inhibitor-for-thyroid-eye-disease/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/sling-therapeutics